BridgeBio Pharma BBIO Reportable Segment — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — revenue?
- BridgeBio Pharma (BBIO) reported reportable segment — revenue of $194.52M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — revenue changed year-over-year?
- BridgeBio Pharma's reportable segment — revenue increased by 66.8% year-over-year, from $116.63M to $194.52M.
- What does reportable segment — revenue mean?
- Total sales generated by the company's main business segment.
- How do you interpret reportable segment — revenue?
- An increase indicates successful commercialization or market expansion, while a decrease suggests slowing demand or competitive pressure.
- How does reportable segment — revenue compare across companies?
- Standard revenue reporting across all biopharmaceutical companies.